TRACON Pharmaceuticals to Present at the Jefferies Healthcare Conference
To access a live webcast or replay of the presentation, please visit the “Events and Presentations” page within the “Investors” section of the
About TRACON
TRACON develops targeted therapies for cancer utilizing a capital efficient, CRO independent, product development platform. The Company’s clinical-stage pipeline includes: Envafolimab, a PD-L1 single-domain antibody given by rapid subcutaneous injection that is being studied in the pivotal ENVASARC trial for sarcoma; YH001, a potential best-in-class CTLA-4 antibody in Phase 1 development; TRC102, a Phase 2 small molecule drug candidate for the treatment of lung cancer; and TJ004309, a CD73 antibody in Phase 1 development for the treatment of advanced solid tumors. TRACON is actively seeking additional corporate partnerships through a profit-share or revenue share partnership, or through franchising TRACON’s product development platform by licensing TRACON’s clinical know-how. TRACON believes it can serve as a solution for companies without clinical and commercial capabilities in
Company Contact: | Investor Contact: |
Chief Business Officer | |
(858) 251-3492 | (212) 915-2578 |
mwiggins@traconpharma.com | britchie@lifesciadvisors.com |
Source: TRACON Pharmaceuticals, Inc.